Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer

Next Previous
Search
Trial Profile

A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CGX 1321 (Primary) ; Cetuximab; Encorafenib; Pembrolizumab
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms Keynote 596
  • Sponsors Curegenix

    • Most Recent Events

    • 06 Jun 2023 Results ( As of January 1, 2023), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 11 Jan 2022 Planned End Date changed from 1 Dec 2022 to 1 Mar 2023.
    • 11 Jan 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top